FDAWatson Pharmaceuticals.

Watson Pharmaceuticals receives a complete response letter for its 24 - Week Formulation TRELSTAR NDA from U.S. FDAWatson Pharmaceuticals , a leading specialty pharmaceutical company, announced that it received a Complete response letter the U.S. Food and Drug Administration for its New Drug Application for TRELSTAR 22.5 mg , a 24-week formulation TRELSTAR for the palliative treatment of advanced prostate cancer. The TRELSTAR NDA with with Debiopharm Group, in Switzerland, and managed global biopharmaceutical company.

Source: Watson Pharmaceuticals,Stephen J.d Exercise Guidelines for Prostate Health Through Prostate Cancer Foundation PublishedThe latest science-based guidelines for diet and exercise as they relate to to prostate health and cancer prevention are now in a new publication from The Prostate Cancer Foundation available. The guide, Nutrition, Exercise and Prostate Cancer is, in electronic form on the foundation's website, individuals can also order a printed copy the online brochure.Courtesy of They can whole Kaiser Daily HealthPolicyMonitor view Reports, search the archives or sign up for mail with an in Imperial Daily Health emphasis policy coverage from on Kaiser network. A free service of of The Henry J. Released. Kaiser Family Foundation.